Quotient Diagnostics - Full Profile
We first came across Quotient Diagnostics in late 2003, a start up company that has developed a more effective test for the monitoring of diabetes. The test in question, for “glycated haemoglobin”, gives clinicians insight into the long-term progress of the disease in a diagnosed patient, as opposed to the short-term picture provided by regular blood glucose testing. The test, known as A1c or HbA1c, has been around for a while, but requires sending samples to a distance laboratory. Quotient’s achievement has been to simplify the test, take it out of the centralized laboratory and make it work in the clinic or doctors surgery (i.e. at the Point of Care).
In July 2009 a fifth round of funding attracted a cross border, €1 million from a group of European investors including French Succès Europe, an angel fund , based out of Sophia Antipolis, and Milan-Italy based IAG (Italian Angels for Growth), and a Swiss angel investor. An existing, strategic corporate investor (BBI Holdings) also participated in this round.